Armata Pharmaceuticals Inc (ARMP) - Total Assets
Based on the latest financial reports, Armata Pharmaceuticals Inc (ARMP) holds total assets worth $76.88 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Armata Pharmaceuticals Inc working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Armata Pharmaceuticals Inc - Total Assets Trend (1993–2025)
This chart illustrates how Armata Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Armata Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Armata Pharmaceuticals Inc's total assets of $76.88 Million consist of 13.9% current assets and 86.1% non-current assets. Also see Armata Pharmaceuticals Inc (ARMP) market capitalisation for the company's overall valuation and market capitalisation.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.3% |
| Accounts Receivable | $472.00K | 0.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $10.26 Million | 13.3% |
| Goodwill | $3.49 Million | 4.5% |
Asset Composition Trend (1993–2025)
This chart illustrates how Armata Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ARMP stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Armata Pharmaceuticals Inc's current assets represent 13.9% of total assets in 2025, a decrease from 57.0% in 1993.
- Cash Position: Cash and equivalents constituted 11.3% of total assets in 2025, up from 9.9% in 1993.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 2.0% in 1993.
- Asset Diversification: The largest asset category is intangible assets at 13.3% of total assets.
Armata Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Armata Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
BRITANNIA LIFE SCIENCES
F:L020
|
Germany | €22.06 Million |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
USA | $2.25 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA
PA:ABVX
|
France | €584.34 Million |
|
ABCELLERA BIOLOGICS
F:8QQ
|
Germany | €1.36 Billion |
Armata Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.19 | 0.23 | 4.83 |
| Quick Ratio | 1.19 | 0.23 | 4.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.72 Million | $-36.94 Million | $19.06 Million |
Armata Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Armata Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.11 |
| Latest Market Cap to Assets Ratio | 3.99 |
| Asset Growth Rate (YoY) | -11.1% |
| Total Assets | $76.88 Million |
| Market Capitalization | $306.77 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Armata Pharmaceuticals Inc's assets at a significant premium (3.99x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Armata Pharmaceuticals Inc's assets decreased by 11.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Armata Pharmaceuticals Inc (1993–2025)
The table below shows the annual total assets of Armata Pharmaceuticals Inc from 1993 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $76.88 Million | -11.05% |
| 2024-12-31 | $86.44 Million | -12.12% |
| 2023-12-31 | $98.36 Million | -8.82% |
| 2022-12-31 | $107.88 Million | +54.62% |
| 2021-12-31 | $69.77 Million | +76.56% |
| 2020-12-31 | $39.52 Million | +55.26% |
| 2019-12-31 | $25.45 Million | +114.11% |
| 2018-12-31 | $11.89 Million | +6.72% |
| 2017-12-31 | $11.14 Million | -38.79% |
| 2016-12-31 | $18.20 Million | -42.23% |
| 2015-12-31 | $31.49 Million | +10.05% |
| 2014-12-31 | $28.62 Million | -24.59% |
| 2013-12-31 | $37.95 Million | +71.93% |
| 2012-12-31 | $22.07 Million | +92.26% |
| 2011-12-31 | $11.48 Million | +110.64% |
| 2009-12-31 | $5.45 Million | -23.78% |
| 2008-12-31 | $7.15 Million | -74.89% |
| 2007-12-31 | $28.47 Million | +63.02% |
| 2006-12-31 | $17.47 Million | -64.21% |
| 2005-12-31 | $48.80 Million | -30.25% |
| 2004-12-31 | $69.97 Million | +21.32% |
| 2003-12-31 | $57.67 Million | +9.41% |
| 2002-12-31 | $52.71 Million | -25.80% |
| 2001-12-31 | $71.04 Million | -19.25% |
| 2000-12-31 | $87.97 Million | +542.15% |
| 1999-12-31 | $13.70 Million | -15.43% |
| 1998-12-31 | $16.20 Million | +65.31% |
| 1997-12-31 | $9.80 Million | -60.96% |
| 1996-12-31 | $25.10 Million | +25.50% |
| 1995-12-31 | $20.00 Million | +17.65% |
| 1994-12-31 | $17.00 Million | +40.50% |
| 1993-12-31 | $12.10 Million | -- |
About Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA03 for Pseudo… Read more